Home・Lista de Ações・Sana Biotechnology Inc

Sana Biotechnology Inc

Abrir

SetorSaúde

4.09 8.2

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.71

Máximo

3.89

Indicadores-chave
By Trading Economics
Rendimento	-16M -64M
EPS	-0.13
Funcionários	142
EBITDA	-17M -61M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+111.64% upside

Dividendos
By Acuity
Próximos Ganhos	4 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	217M 1.1B
Abertura anterior	-4.11
Fecho anterior	4.09

Sentimento de Notícias

By Acuity

25%

75%

73 / 340 Ranking em Healthcare

Sana Biotechnology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de ago. de 2026, 19:36 UTC

Correlated Moves

Sana Biotechnology Inc's shares are lower today, reflecting broader declines in the biotech sector, including a drop in the ARK Genomic Revolution ETF.

21 de ago. de 2026, 23:36 UTC

Sana Biotechnology Inc. shares moved lower in after-market trading, despite resilience in major stocks like Tesla and UnitedHealth. The price remains above its 20-day moving average.

20 de ago. de 2026, 23:01 UTC

Sana Biotechnology Inc. shares are higher in after-hours trading, driven by gains in the Biotechnology sub-sector and remaining above its 20-day moving average.

19 de ago. de 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, following a notable decline from earlier highs. No specific news was identified to explain the move.

18 de ago. de 2026, 19:46 UTC

Sana Biotechnology Inc. shares are lower today, reflecting a decline since Monday amid rising Treasury yields and ongoing inflation concerns.

17 de ago. de 2026, 23:46 UTC

Sana Biotechnology Inc shares are slightly higher in after-market hours. No specific news was identified to explain the movement.

14 de ago. de 2026, 20:06 UTC

News

Sana Biotechnology shares declined amid mixed analyst ratings and broader market challenges, with BofA lowering its price target to $6.00 from $7.00.

13 de ago. de 2026, 19:36 UTC

Sana Biotechnology Inc shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

12 de ago. de 2026, 23:46 UTC

Sana Biotechnology Inc shares are lower in after-market hours, with no specific news identified to explain the price movement.

11 de ago. de 2026, 19:31 UTC

News

Sana Biotechnology shares are higher following Q2 results showing an adjusted EPS of -$0.13, exceeding estimates, and a $25 million investment from Mayo Clinic.

10 de ago. de 2026, 23:01 UTC

News

Sana Biotechnology Inc shares are lower in after-market hours following a second-quarter loss of $63.6 million, despite an adjusted EPS that exceeded expectations.

7 de ago. de 2026, 19:56 UTC

Sana Biotechnology Inc. shares are higher, supported by broader market dynamics following a disappointing jobs report easing interest rate concerns.

5 de ago. de 2026, 19:56 UTC

Sana Biotechnology Inc. is trading higher during Wednesday's session, having peaked earlier before pulling back slightly while remaining above its 20-day moving average.

4 de ago. de 2026, 20:05 UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

3 de ago. de 2026, 19:46 UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

31 de jul. de 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

30 de jul. de 2026, 19:29 UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

29 de jul. de 2026, 23:36 UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

28 de jul. de 2026, 18:03 UTC

Sana Biotechnology Inc. shares are higher as biotechnology stocks advance, though they diverge from a recent trend of daily gains since Monday's close.

27 de jul. de 2026, 19:07 UTC

Sana Biotechnology Inc shares are higher today, continuing a rally since Friday. No specific news has been identified to explain the price movement.

24 de jul. de 2026, 18:26 UTC

Sana Biotechnology Inc. shares are trading lower amid broader market volatility, with no specific company news identified to explain the decline.

22 de jul. de 2026, 19:36 UTC

News

Sana Biotechnology has shifted focus to B-cell autoimmune disorders amid competition in oncology. Shares are higher since Tuesday, supported by rising crude oil prices.

20 de jul. de 2026, 17:56 UTC

Social Media

Sana Biotechnology Inc shares are lower, continuing a nine-session decline. Social media discussions raise skepticism about the timeline for its allogeneic cell therapies.

Comparação entre Pares

Variação de preço

Sana Biotechnology Inc Previsão

Preço-alvo

By TipRanks

111.64% parte superior

Previsão para 12 meses

Média 8 USD 111.64%

Máximo 12 USD

Mínimo 6 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Sana Biotechnology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Sana Biotechnology Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

73 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.